PPARA and hyperlipidemia: Fenofibrate is a peroxisome proliferator-activated receptor-α (PPAR-α) agonist approved by the Food and Drug Administration (FDA) to routinely treat hyperlipidemia with elevated triglycerides (TGs), or mixed hyperlipidemia with elevated TGs and reduced high-density lipoprotein cholesterol (HDL-C) levels [1].